Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $100.30 | Total: $501.50 |
| 1 | 10 | $84.96 | Total: $849.60 |
| 1 | 25 | $71.98 | Total: $1,799.50 |
| 1 | 50 | $61.36 | Total: $3,068.00 |
| 1 | 100 | $53.10 | Total: $5,310.00 |
Overview
Mithramycin A (Plicamycin), a DNA-binding antitumor antibiotic, is a selective specificity protein 1 (Sp1) inhibitor, which inhibits the growth of various cancers by decreasing Sp1 protein. Specificity protein 1 (Sp1) is a zinc-finger transcription factor that regulates multiple cellular functions and promotes tumor progression.
Chemical Properties
| Molecular Formula | C52H76O24 |
| Molecular Weight | 1085.15 |
| CAS Numbers | 18378-89-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [H][C@@]1(C[C@@H](O)[C@H](O)[C@@H](C)O1)O[C@@H]1C[C@]([H])(Oc2cc3cc4C[C@@]([H])([C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H](O[C@@]5([H])C[C@@H](O[C@@]6([H])C[C@@H](O[C@@]7([H])C[C@](C)(O)[C@H](O)[C@@H](C)O7)[C@@H](O)[C@@H](C)O6)[C@H](O)[C@@H](C)O5)C(=O)c4c(O)c3c(O)c2C)O[C@H](C)[C@H]1O |
Storage and Handling
0C Short Term, -20C Long Term
References
Choi ES, et al. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 2014 Nov 24;4 7162.